Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of splenectomy in benign and malignant hematologic conditions in the immunotherapy era

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJohn Rutledge

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis indicates decreased splenectomy rates and infection complications in hematologic patients post-immunotherapy.

Key Points

  • This research analyzes complication rates and trends in splenectomy related to immunotherapy in hematologic diseases.
  • Retrospective cohort study using ACS NSQIP database.
  • Compared splenectomy outcomes pre- and post-immunotherapy approval.
  • Included adults with benign or malignant hematologic conditions.
  • Splenectomies decreased by 51.04% for malignant conditions between groups.
  • Leukemia infection rates increased by 17.6% post-immunotherapy (p=0.03).
  • Bleeding rates significantly decreased by 10.7% for lymphoma cases post-immunotherapy.

Cite This Study

John Rutledge (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfe6https://doi.org/10.1182/blood-2025-4462
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of Splenectomy for Hematologic Malignancies2026
  2. 2Pediatric splenectomy for hematologic disorders: two-decade experience and prophylactic cholecystectomy outcomes2025
  3. 3P-2123. Splenectomy in Cancer Patients. Is It Associated with a High Risk of Infection?2026
  4. 4Impact of splenectomy on hematological outcomes and monoclonal gammopathy of undetermined significance development in patients with immune thrombocytopenic purpura2026
  5. 5Efficacy and Complications of Open vs. Laparoscopic Splenectomy: A Systematic Review2025